Based on this, MET-targeted inhibitors have been used in HCC clinical trials, and FIS1 has been identified as a novel, significant downstream target that is regulated by MET kinase (Deldar Abad Paskeh et al., 2021). This evidence concerns the gene FIS1 and hepatocellular carcinoma.